Immutep Limited IMM.AX Stock
Immutep Limited Price Chart
Immutep Limited IMM.AX Financial and Trading Overview
Immutep Limited stock price | 0.36 AUD |
Previous Close | 0.3 AUD |
Open | 0.3 AUD |
Bid | 0.3 AUD x 0 |
Ask | 0.3 AUD x 0 |
Day's Range | 0.29 - 0.3 AUD |
52 Week Range | 0.23 - 0.42 AUD |
Volume | 1.18M AUD |
Avg. Volume | 2.01M AUD |
Market Cap | 267.94M AUD |
Beta (5Y Monthly) | 2.041762 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.04 AUD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.23 AUD |
IMM.AX Valuation Measures
Enterprise Value | 196.37M AUD |
Trailing P/E | N/A |
Forward P/E | -10.000001 |
PEG Ratio (5 yr expected) | -1.97 |
Price/Sales (ttm) | 60.367104 |
Price/Book (mrq) | 3.448276 |
Enterprise Value/Revenue | 44.241 |
Enterprise Value/EBITDA | -5.247 |
Trading Information
Immutep Limited Stock Price History
Beta (5Y Monthly) | 2.041762 |
52-Week Change | -3.22% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.42 AUD |
52 Week Low | 0.23 AUD |
50-Day Moving Average | 0.27 AUD |
200-Day Moving Average | 0.28 AUD |
IMM.AX Share Statistics
Avg. Volume (3 month) | 2.01M AUD |
Avg. Daily Volume (10-Days) | 3.7M AUD |
Shares Outstanding | 893.14M |
Float | 847.94M |
Short Ratio | N/A |
% Held by Insiders | 4.61% |
% Held by Institutions | 24.37% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -862.75% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -23.21% |
Return on Equity (ttm) | -39.40% |
Income Statement
Revenue (ttm) | 4.44M AUD |
Revenue Per Share (ttm) | 0.005 AUD |
Quarterly Revenue Growth (yoy) | -11.50% |
Gross Profit (ttm) | -26627215 AUD |
EBITDA | -37424136 AUD |
Net Income Avi to Common (ttm) | -36563864 AUD |
Diluted EPS (ttm) | -0.05 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 68.38M AUD |
Total Cash Per Share (mrq) | 0.08 AUD |
Total Debt (mrq) | 952.66K AUD |
Total Debt/Equity (mrq) | 1.24 AUD |
Current Ratio (mrq) | 8.974 |
Book Value Per Share (mrq) | 0.087 |
Cash Flow Statement
Operating Cash Flow (ttm) | -30356748 AUD |
Levered Free Cash Flow (ttm) | -18779684 AUD |
Profile of Immutep Limited
Country | Australia |
State | NSW |
City | Sydney |
Address | Australia Square |
ZIP | 2000 |
Phone | 61 2 8315 7003 |
Website | https://www.immutep.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.
Q&A For Immutep Limited Stock
What is a current IMM.AX stock price?
Immutep Limited IMM.AX stock price today per share is 0.36 AUD.
How to purchase Immutep Limited stock?
You can buy IMM.AX shares on the ASX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Immutep Limited?
The stock symbol or ticker of Immutep Limited is IMM.AX.
Which industry does the Immutep Limited company belong to?
The Immutep Limited industry is Biotechnology.
How many shares does Immutep Limited have in circulation?
The max supply of Immutep Limited shares is 1.19B.
What is Immutep Limited Price to Earnings Ratio (PE Ratio)?
Immutep Limited PE Ratio is now.
What was Immutep Limited earnings per share over the trailing 12 months (TTM)?
Immutep Limited EPS is -0.04 AUD over the trailing 12 months.
Which sector does the Immutep Limited company belong to?
The Immutep Limited sector is Healthcare.